ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2026)

ARS Pharmaceuticals has disclosed Net Margin across 5 years of filings, most recently posting 275.94% for Q1 2026.

• Net Margin for Q1 2026 came in at 275.94%, up 19035.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 62.03% (down 3416.0% YoY), and the FY2025 annual result was 203.25%, down 21222.0% from the prior year.
• Net Margin came in at 275.94% for Q1 2026 at ARS Pharmaceuticals, down from 363.14% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 363.14% in Q4 2025 to a low of 206030.0% in Q2 2023.
• The 5-year median for Net Margin is 1051.64% (2024), against an average of 23880.9%.
• Across the five-year window, Net Margin plunged 20466276 bps in 2023 and soared 20296200 bps in 2024, its largest moves.
• ARS Pharmaceuticals' Net Margin stood at 3507.94% in 2022, then slumped by 5773 bps to 206030.0% in 2023, then jumped by 100 bps to 54.51% in 2024, then surged by 566 bps to 363.14% in 2025, then plunged by 176 bps to 275.94% in 2026.
• The last three Net Margin figures came in at 275.94% (Q1 2026), 363.14% (Q4 2025), and 163.66% (Q3 2025), per Business Quant data.